NUMERAL LIMITED - Update on Healthcare and Biotech Strategy, Investments and the Finalisation of Audited Results
What this filing means
Numeral has delayed its 28 February 2026 audited results to on or about 15 July, blaming the accounting treatment of two investments — Longevity and Isopharm — where the board could not get usable information from the founder and has since settled to recover its money. The rest of the update outlines strategic progress: Boost & Recovery's Kyalami flagship is targeted within 60 days, Cryo-Save crossed to 51% control, and WestMed is a new healthcare investment — but no financial figures are disclosed.
Imagine a company that promised its annual results months ago and keeps pushing the date. That's Numeral — its February year-end accounts are now due around 15 July, with the hold-up attributed to two investments where management couldn't get usable information from the founder — it has settled to recover its money. The rest — a new wellness brand, a healthcare stake, biotech hitting 51% — is forward-looking colour, not earnings.
Bull case
- Boost & Recovery's Kyalami flagship sits on a firm 60-day completion clock, with Sandton City and Camps Bay already mapped — a concrete near-term revenue catalyst.
- Cryo-Save crossed to 51% control and is described as the biotech cornerstone enjoying 'solid growth', consolidating earnings into Numeral.
- First strategic investment into WestMed opens a primary healthcare, specialist, aesthetic and regenerative medicine vertical aligned with the long-term platform thesis.
- Resolution of the Longevity/Isopharm accounting blockage — flagged as the main audit delay — clears a multi-month information overhang ahead of the 15 July 2026 finalisation.
Bear case
- Audited results are targeted only for 15 July 2026 — roughly five months after year-end — leaving revenue, cash, and debt position completely unverified in this update.
- The Board determined it has neither IFRS 10 control nor IAS 28 significant influence over Longevity and Isopharm, evidencing a prior capital deployment without adequate information or governance rights.
- Management's post-year-end settlement to 'recover' investments in Longevity and Isopharm implicitly concedes impairment exposure; quantum, probability, and timing of any recovery are undisclosed.
- The Boost & Recovery flagship at Kyalami is still under development, with Sandton City and Camps Bay only 'planned' — no unit economics, capex, or funding visibility behind the rollout strategy.
AI-generated summary by SENS-AI, based on the original JSE SENS filing.
SENS-AI conclusion
A strategic update with no financial figures, on a company that has delayed its February 2026 audited results until mid-July. Boost & Recovery and WestMed are forward-looking without unit economics, and the Cryo-Save 51% stake was previously flagged — progress markers, not fresh re-rating signals. The Longevity/Isopharm exit matters more: management conceding it cannot get usable information from a founder, then settling post year-end to recover capital, hints at capital deployment that did not work as planned. So what: the 15 July audited results are where the market will test whether the strategy is matched by earnings. Missing evidence: No revenue, EBITDA, profit, HEPS, EPS or any earnings metrics disclosed; No cash, debt, working capital or balance sheet figures provided; No dividend declaration or policy guidance included; No prior trading statement range to assess surprise against; No forward financial guidance or earnings outlook provided
The 15 July 2026 audited results will reveal whether the strategic narrative is supported by earnings, cash flow, and the cost basis of Longevity/Isopharm.
Evidence from the filing
Boost & Recovery's Kyalami flagship sits on a firm 60-day completion clock, with Sandton City and Camps Bay already mapped — a concrete near-term revenue catalyst.
“The first flagship facility is currently under development at Kyalami, with completion expected within the next 60 days.”
Cryo-Save crossed to 51% control and is described as the biotech cornerstone enjoying 'solid growth', consolidating earnings into Numeral.
“The shareholding in Cryo-Save was increased to 51% during the year ended 28 February 2026 as expected.”
First strategic investment into WestMed opens a primary healthcare, specialist, aesthetic and regenerative medicine vertical aligned with the long-term platform thesis.
“The Board has decided to exit its investments in Longevity and Isopharm due to the inability to secure timely operational and financial information from the founder for purposes of consolidation.”
Resolution of the Longevity/Isopharm accounting blockage — flagged as the main audit delay — clears a multi-month information overhang ahead of the 15 July 2026 finalisation.
“The accounting treatment of the two investments in Longevity and Isopharm has been one of the major delaying factors.”
Audited results are targeted only for 15 July 2026 — roughly five months after year-end — leaving revenue, cash, and debt position completely unverified in this update.
“The audited results are targeted to be finalised on or about 15 July 2026.”
The Board determined it has neither IFRS 10 control nor IAS 28 significant influence over Longevity and Isopharm, evidencing a prior capital deployment without adequate information or governance rights.
“The Board has thus determined that it does not have control as envisaged in IFRS 10, nor significant influence in terms of IAS 28, and has accounted for the two companies as investments in its results for the year ended 28 February 2026.”
Management's post-year-end settlement to 'recover' investments in Longevity and Isopharm implicitly concedes impairment exposure; quantum, probability, and timing of any recovery are undisclosed.
“Management decided to enter into a settlement agreement with the founder subsequent to year end to recover its investments as opposed to forcing operational control on the founder and potentially destroying the underlying businesses.”
More on Numeral Limited
Related filings
More from XII
- NUMERAL LIMITED - Results of Annual Meeting of Shareholders
- NUMERAL LIMITED - Issue of Shares for Cash Extension of Closing Date
- NUMERAL LIMITED - Short Form - Summary of the Unaudited Abridged Financial Statements for the Three Months Ended 31 May 2026
- NUMERAL LIMITED - No Change Statement, Posting of Annual Report and Notice of Annual Meeting
- NUMERAL LIMITED - Short Form Announcement - Availability of the Annual Report for the Year Ended 28 February 2026